International Journal of Pediatrics [35] S. Johnson, C. Oliver, G. A. Prince et al., “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus,” Journal of Infectious Diseases, vol. 176, no. 5, pp. 1215–1224, 1997. [36] E. A. F. Simoes, H. M. Sondheimer, F. H. Top et al., “Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease infants and children with congenital heart disease,” Journal of Pediatrics, vol. 133, no. 4, pp. 492–499, 1998. [37] S. A. Cohen, R. Zanni, A. Cohen, M. Harrington, P. Vanveld- huisen, and M. L. Boron, “Palivizumab use in subjects with congenital heart disease,” Pediatric Cardiology, vol. 29, no. 2, pp. 382–387, 2008. [38] R.-K. R. Chang and A. Y. Chen, “Impact of palivizumab on RSV hospitalizations for children with hemodynamically signiﬁcant congenital heart disease,” Pediatric Cardiology, vol. 31, no. 1, pp. 90–95, 2010. [39] T. Saji, M. Nakazawa, and K. Harada, “Safety and eﬃcacy of palivizumab prophylaxis in children with congenital heart disease,” Pediatrics International, vol. 47, no. 4, pp. 397–403, 2005. [40] T. Saji, M. Nakazawa, and K. Harada, “Nationwide survey of palivizumab for respiratory syncytial virus prevention in japanese children with congenital heart disease,” Pediatric Infectious Disease Journal, vol. 27, no. 12, pp. 1108–1109, 2008. [41] American Academy of Pediatrics, Committee on Infectious Diseases, “Policy statement—modiﬁed recommendations for use of palivizumab for prevention of respiratory syncytial virus infections,” Pediatrics, vol. 124, no. 6, pp. 1694–1701, 2009. [42] J. M. Geskey, G. D. Ceneviva, G. Brummel, G. R. Graﬀ, and M. C. Javier, “Administration of the ﬁrst dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its beneﬁt?” Clinical Therapeutics, vol. 26, no. 12, pp. 2130–2137, 2004. [43] M. P. Frogel, D. L. Stewart, M. Hoopes, A. W. Fernandes, and P. J. Mahadevia, “A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis,” Journal of Managed Care Pharmacy, vol. 16, no. 1, pp. 46–58, 2010. [44] H. Wu, D. S. Pfarr, S. Johnson et al., “Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract,” Journal of Molecular Biology, vol. 368, no. 3, pp. 652–665, 2007. [45] T. F. Feltes, H. M. Sondheimer, R. M. R. Tulloh et al., “A ran- domized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus dis- ease in children with hemodynamically signiﬁcant congenital heart disease,” Pediatric Research, vol. 70, no. 2, pp. 186–191, 2011. [46] Q. Zhu, J. M. McAuliﬀe, N. K. Patel et al., “Analysis of respira- tory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab,” Journal of Infectious Diseases, vol. 203, no. 5, pp. 674–682, 2011. [47] J. M. Geskey, N. J. Thomas, and G. L. Brummel, “Palivizumab in congenital heart disease: should international guidelines be revised?” Expert Opinion on Biological Therapy, vol. 7, no. 11, pp. 1615–1620, 2007. 7 [48] A. Duppenthaler, R. A. Ammann, M. Gorgievski-Hrisoho, J. P. Pfammatter, and C. Aebi, “Low incidence of respiratory syn- cytial virus hospitalisations in haemodynamically signiﬁcant congenital heart disease,” Archives of Disease in Childhood, vol. 89, no. 10, pp. 961–965, 2004. [49] D. Y. Tam, A. Banerji, B. A. Paes, C. Hui, J. E. Tarride, and K. L. Lanctoˆ t, “The cost eﬀectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic,” Journal of Medical Economics, vol. 12, no. 4, pp. 361–370, 2009. [50] C. Hampp, T. L. Kauf, A. S. Saidi, and A. G. Winterstein, “Cost-eﬀectiveness of respiratory syncytial virus prophylaxis in various indications,” Archives of Pediatrics and Adolescent Medicine, vol. 165, no. 6, pp. 498–505, 2011. [51] B. Resch, W. Gusenleitner, M. J. C. Nuijten, M. Lebmeier, and W. Wittenberg, “Cost-eﬀectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria,” Clinical Therapeutics, vol. 30, no. 4, pp. 749–760, 2008. [52] R. M. R. Tulloh and T. F. Feltes, “The European forum for clinical management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease,” Cardiology in the Young, vol. 15, no. 3, pp. 274–278, 2005. [53] T. M. Berger, C. Aebi, A. Duppenthaler, and M. Stocker, “Prospective population-based study of RSV-related interme- diate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005),” Infection, vol. 37, no. 2, pp. 109–116, 2009. [54] R. T. Stein, D. Sherrill, W. J. Morgan et al., “Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years,” The Lancet, vol. 354, no. 9178, pp. 541–545, 1999. [55] M. Korppi, E. Piippo-Savolainen, K. Korhonen, and S. Remes, “Respiratory morbidity 20 years after RSV infection in infancy,” Pediatric Pulmonology, vol. 38, no. 2, pp. 155–160, 2004. [56] L. A. Rosenthal, P. C. Avila, P. W. Heymann et al., “Viral respiratory tract infections and asthma: the course ahead,” Journal of Allergy and Clinical Immunology, vol. 125, no. 6, pp. 1212–1217, 2010. [57] E. A. F. Simoes, X. Carbonell-Estrany, C. H. L. Rieger, I. Mitchell, L. Fredrick, and J. R. Groothuis, “The eﬀect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children,” Journal of Allergy and Clinical Immunology, vol. 126, no. 2, pp. 256–262, 2010. [58] B. S. Graham, “Biological challenges and technological oppor- tunities for respiratory syncytial virus vaccine development,” Immunological Reviews, vol. 239, no. 1, pp. 149–166, 2011. [59] J. Chin, R. L. Magoﬃn, L. A. Shearer, J. H. Schieble, and E. H. Lennette, “Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainﬂuenza virus vaccine in a pediatric population,” American Journal of Epidemiology, vol. 89, no. 4, pp. 449–463, 1969. [60] V. A. Fulginiti, J. J. Eller, O. F. Sieber, J. W. Joyner, M. Mina- mitani, and G. Meiklejohn, “Respiratory virus immunization. I. A ﬁeld trial of two inactivated respiratory virus vaccines; an aqueous trivalent paratnﬂuenza virus vaccine and an alum- precipitated respiratory syncytial virus vaccine,” American Journal of Epidemiology, vol. 89, no. 4, pp. 435–448, 1969. [61] S. D. Little-van den Hurk, J. W. Mapletoft, N. Arsic, and J. Kovacs-Nolan, “Immunopathology of RSV infection: prospects for developing vaccines without this complication,” Reviews in Medical Virology, vol. 17, no. 1, pp. 5–34, 2007.